LID

RECOM Technologies LION HJT PV Module Series with power output over 700Wp & life expectancy over 30 years

Retrieved on: 
Monday, October 24, 2022
ISO, Time, PV, Efficiency, LCOE, LION, Silicon, No, HJT, Technology, EV, Lion, PID, Snow, Heterojunction, ISO 9001, LID, Renewable energy

LANNION, France, Oct. 24, 2022 /PRNewswire/ -- RECOM Technologies, α leading renewable energy company and the only European Bloomberg Tier 1 PV module manufacturer, launches the new LION 390Wp Bifacial HJT Mono Crystalline Double Glass Module. Allowing more energy to be harvested, due to the Heterojunction technology (HJT), the LION 390Wp promises great performance in small and large-scale ground or rooftop solar applications.

Key Points: 
  • Lion series modules with power output over 700Wp are based on Heterojunction (HJT) technology.
  • Heterojunction (HJT) photovoltaic module is a ground breaking technology as it guarantees high performance and low degradation of the PV module, substantially improving the results and the yield in the time.
  • RECOM Technologies Lion series range is available from 375Wp and goes above 700Wp.
  • RECOM's power plants are certified to ISO 9001 and 14001 standards and Lion series is fully certified to IEC61215 & 61730 standards.

BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled

Retrieved on: 
Wednesday, October 19, 2022
NF-κB, L-DOPA, SEC, PD, Dyskinesia, Liver disease, Hand, Neurodegeneration, Insulin resistance, Primate, NASDAQ, MPTP, Patient, Parkinson's disease, ALS, Inflammation, TNF, Neuron, Company, Trial of the century, ERK, 8-K, Health, Microglia, Fast track (FDA), Degenerative disease, Alzheimer's disease, CEO, Cirrhosis, Safety, Neuroinflammation, LID, Ascites, AD, Survival, GLOBE, Oxidative stress, FDA, Pathology, Human, Pharmaceutical industry

Safety assessments will evaluate standard measures of patient health and potential for drug-drug interactions affecting L-dopa PK and activity.

Key Points: 
  • Safety assessments will evaluate standard measures of patient health and potential for drug-drug interactions affecting L-dopa PK and activity.
  • Efficacy assessments use the Motor Disease Society Unified Parkinsons Disease Rating (MDS-UPDRS) parts 1-3, ON/OFF Diary, and Non-Motor Symptom Scale.
  • Commenting on the PD trial progress, Cuong Do, BioVies President and CEO, said To date, we have seen no drug-related adverse events in reviews.
  • A Phase 2 study of NE3107 in Parkinsons disease (NCT05083260) is fully enrolled and expects to have topline data readout in December 2022.

RECOM Technologies LION HJT PV Module Series with power output over 700Wp & life expectancy over 30 years

Retrieved on: 
Monday, October 17, 2022
ISO, Time, PV, Efficiency, LCOE, LION, Silicon, No, HJT, Technology, EV, Lion, PID, Snow, Heterojunction, ISO 9001, LID, Renewable energy

LANNION, France, Oct. 17, 2022 /PRNewswire/ -- RECOM Technologies, α leading renewable energy company and the only European Bloomberg Tier 1 PV module manufacturer, launches the new LION 390Wp Bifacial HJT Mono Crystalline Double Glass Module. Allowing more energy to be harvested, due to the Heterojunction technology (HJT), the LION 390Wp promises great performance in small and large-scale ground or rooftop solar applications.

Key Points: 
  • Lion series modules with power output over 700Wp are based on Heterojunction (HJT) technology.
  • Heterojunction (HJT) photovoltaic module is a ground breaking technology as it guarantees high performance and low degradation of the PV module, substantially improving the results and the yield in the time.
  • RECOM Technologies Lion series range is available from 375Wp and goes above 700Wp.
  • RECOM's power plants are certified to ISO 9001 and 14001 standards and Lion series is fully certified to IEC61215 & 61730 standards.

RECOM Technologies LION HJT PV Module Series with power output over 700Wp & life expectancy over 30 years

Retrieved on: 
Monday, October 17, 2022
ISO, Time, PV, Efficiency, LCOE, LION, Silicon, No, HJT, Technology, EV, Lion, PID, Snow, Heterojunction, ISO 9001, LID, Renewable energy

LANNION, France, Oct. 17, 2022 /PRNewswire/ -- RECOM Technologies, α leading renewable energy company and the only European Bloomberg Tier 1 PV module manufacturer, launches the new LION 390Wp Bifacial HJT Mono Crystalline Double Glass Module. Allowing more energy to be harvested, due to the Heterojunction technology (HJT), the LION 390Wp promises great performance in small and large-scale ground or rooftop solar applications.

Key Points: 
  • Lion series modules with power output over 700Wp are based on Heterojunction (HJT) technology.
  • Heterojunction (HJT) photovoltaic module is a ground breaking technology as it guarantees high performance and low degradation of the PV module, substantially improving the results and the yield in the time.
  • RECOM Technologies Lion series range is available from 375Wp and goes above 700Wp.
  • RECOM's power plants are certified to ISO 9001 and 14001 standards and Lion series is fully certified to IEC61215 & 61730 standards.

PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease

Retrieved on: 
Wednesday, October 5, 2022
Diamond, Neurogenic bladder dysfunction, Lists of diseases, Ketamine, Substantia nigra, Hypertension, Movement, Constipation, L-DOPA, Orthostatic hypotension, Drug combination, Hypokinesia, Dyskinesia, Substance, Patient, University, Depression, Levodopa-induced dyskinesia, Central nervous system, Mental health, Rigidity, Dopamine, Trial of the century, Neuron, Company, CSE, Pain, Patent, NDMA, Brain, Dysautonomia, FDA, USD, Psychiatry, OTCQB, Tremor, LID, Pharmaceutical industry

TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, is pleased to announce that the United States Patent and Trademark Office (“USPTO”) granted US Patent No: 11,426,366, titled “Compositions and Methods for Treating Motor Disorders,” which includes claims intended to cover ketamine in the potential treatment of Parkinson’s Disease and motor disorders that cause involuntary or uncontrollable movement or actions of the body (the “Patent”).

Key Points: 
  • In August 2020, the Company entered into an exclusive license agreement with the University of Arizona to develop and commercialize the Patent.
  • Parkinsons disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide.
  • The possible therapeutic effect of low-dose ketamine on levodopa-induced dyskinesia was noted in a retrospective analysis of Parkinsons disease patients who received ketamine for pain relief.
  • There is currently no cure for Parkinsons disease, although some drug combinations are used to treat the disease symptoms.

InventHelp Inventor Develops Improved Design for a Beverage Cup Lid (BEC-169)

Retrieved on: 
Friday, September 16, 2022
Sale, Multimedia, Ninth Street, LID, COFFEE, Food, Tea

PITTSBURGH, Sept. 16, 2022 /PRNewswire/ -- "I wanted to create a quick and easy way to find the opening on a beverage cup lid at night or during the early morning hours," said an inventor, from Fairhaven, Mass., "so I invented the FLUORESCENT COFFEE CUP/ LID.

Key Points: 
  • PITTSBURGH, Sept. 16, 2022 /PRNewswire/ -- "I wanted to create a quick and easy way to find the opening on a beverage cup lid at night or during the early morning hours," said an inventor, from Fairhaven, Mass., "so I invented the FLUORESCENT COFFEE CUP/ LID.
  • My design would eliminate the hassle of turning the cup in order to find the lid opening."
  • The patent-pending invention provides an improved design for a beverage cup lid.
  • The invention features an eye-catching design that is easy to use so it is ideal for households, food and beverage establishments, travelers, etc.

PharmaTher Announces Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress of Parkinson

Retrieved on: 
Friday, September 16, 2022
Diamond, Motor disorder, Central nervous system, L-DOPA, Trial of the century, Ketamine, Lists of diseases, Movement, Brain, FDA, Drug combination, Psychiatry, OTCQB, Company, Hypokinesia, Rigidity, Hypertension, LID, MDS, Tremor, Levodopa-induced dyskinesia, Patient, Dopamine, Mental health, USD, Dyskinesia, Neurogenic bladder dysfunction, USPTO, CSE, Method, Pain, United States Patent and Trademark Office, Patent, NDMA, Dysautonomia, Substance, Disease, Orthostatic hypotension, Constipation, University, Neuron, Parkinson's disease, Depression, Substantia nigra, Pharmaceutical industry

TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty ketamine pharmaceuticals, today announced that the Phase 1/2 clinical Study of ketamine in the treatment of levodopa-induced dyskinesia in Parkinson’s disease was presented as a late-breaking abstract presentation at the MDS International Congress of Parkinson's Disease and Movement Disorders®. The congress is being held in Madrid, Spain and virtually between September 15 and 18, 2022.

Key Points: 
  • The late-breaking abstract, LBA-3: Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced, presented at MDS International Congress of Parkinson's Disease and Movement Disorders is available on the meeting website .
  • As previously announced, the United States Patent and Trademark Office (USPTO) has provided a Notice of Allowance for patent application No.
  • Parkinsons disease is a debilitating disorder that affects an estimated 1 million people in the U.S. and 10 million people worldwide.
  • There is currently no cure for Parkinsons disease, although some drug combinations are used to treat the disease symptoms.

PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

Retrieved on: 
Wednesday, July 13, 2022
Diamond, Ketamine, United States Patent and Trademark Office, Drug combination, Tremor, Motor disorder, Method, Patient, Hypokinesia, Observational study, Substance, Mental health, Pain, Central nervous system, Holding, USD, Movement, US, Substantia nigra, Rigidity, Neurogenic bladder dysfunction, Company, L-DOPA, Lists of diseases, CEO, Brain, GLOBE, Patent, Backlog of unexamined patent applications, Pain disorder, Levodopa-induced dyskinesia, Dysautonomia, Safety, Dopamine, Orthostatic hypotension, NDMA, Dyskinesia, Neuron, CSE, Depression, FDA, University, OTCQB, Psychiatry, LID, Congress, Trial of the century, Movement disorders, USPTO, Constipation, Pharmaceutical industry, Study

15/574,346, titled Compositions and Methods for Treating Motor Disorders, which includes claims intended to cover ketamine in the potential treatment of Parkinsons Disease and motor disorders that cause involuntary or uncontrollable movement or actions of the body (the Patent).

Key Points: 
  • 15/574,346, titled Compositions and Methods for Treating Motor Disorders, which includes claims intended to cover ketamine in the potential treatment of Parkinsons Disease and motor disorders that cause involuntary or uncontrollable movement or actions of the body (the Patent).
  • PharmaTher is advancing the development of ketamine for the potential treatment of Parkinsons disease.
  • The Study evaluated the safety, tolerability and efficacy of low-dose ketamine infusion for the treatment of LID in patients with Parkinsons disease.
  • We are focused on advancing a potential Phase 3 clinical study for ketamine in the treatment of levodopa-induced dyskinesia in patients with Parkinsons disease.

Yingli Won the High Achiever Award of RETC PMIR 2022

Retrieved on: 
Tuesday, July 5, 2022
Efficiency, LID, IEC, Lists of stars, RETC, Yingli, PV, Renewable energy, LATAM (disambiguation)

BAODING, China, July 5, 2022 /PRNewswire/ -- Recently, the "2022 PV Module Index Report " was released by Renewable Energy Test Center (RETC).

Key Points: 
  • BAODING, China, July 5, 2022 /PRNewswire/ -- Recently, the "2022 PV Module Index Report " was released by Renewable Energy Test Center (RETC).
  • Yingli won the "High Achiever" award for the year again with its excellent performance in three dimensions of quality indicators, performance indicators and reliability indicators, becoming one of the top six performers of the year.
  • The indicators include 11 categories such as module efficiency, LID resistance, and dump heat test, etc.
  • In addition to being recognized in all three dimensions, Yingli has also won 7 individual outstanding performance awards, and has been listed in the Top list for two consecutive years.

Yingli Won the High Achiever Award of RETC PMIR 2022

Retrieved on: 
Tuesday, July 5, 2022
Efficiency, LID, IEC, Lists of stars, RETC, Yingli, PV, Renewable energy, LATAM (disambiguation)

BAODING, China, July 5, 2022 /PRNewswire/ -- Recently, the "2022 PV Module Index Report " was released by Renewable Energy Test Center (RETC).

Key Points: 
  • BAODING, China, July 5, 2022 /PRNewswire/ -- Recently, the "2022 PV Module Index Report " was released by Renewable Energy Test Center (RETC).
  • Yingli won the "High Achiever" award for the year again with its excellent performance in three dimensions of quality indicators, performance indicators and reliability indicators, becoming one of the top six performers of the year.
  • The indicators include 11 categories such as module efficiency, LID resistance, and dump heat test, etc.
  • In addition to being recognized in all three dimensions, Yingli has also won 7 individual outstanding performance awards, and has been listed in the Top list for two consecutive years.